<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39459597</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-1729</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>13</Day></PubDate></JournalIssue><Title>Life (Basel, Switzerland)</Title><ISOAbbreviation>Life (Basel)</ISOAbbreviation></Journal><ArticleTitle>Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1297</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/life14101297</ELocationID><Abstract><AbstractText>(1) Background: The purpose of this study is to compare the rate of COVID-19 vaccination among psoriasis patients internationally and to correlate it with their treatment regimens. (2) Methods: We conducted a cross-sectional study from January 2021 to October 2022 among adults in the United States (US), Chile, China, Switzerland, and Singapore using the Global Healthcare Study on Psoriasis survey. (3) Results: A total of 310 psoriasis patients in the US (98), Chile (32), China (80), Switzerland (39), and Singapore (61) were surveyed. Of these, 248 patients (80.0%) were vaccinated at least once for COVID-19 (Chile: 100%, Singapore: 100%, US: 93.9%, Switzerland: 69.2%, China: 45.0%). Compared with other countries, patients in China were 89% less likely to report at least one COVID-19 vaccination (1 - 0.11 = 0.89; OR 0.11; 95% CI: 0.03-0.48), and patients in Switzerland were 80% less likely (1 - 0.20 = 0.80; OR 0.20; 95% CI: 0.05-0.79). Compared with patients on biologics, patients on topicals were 10.9 (95% CI: 2.1-56.6) times more likely to report at least one COVID-19 vaccination, and patients on oral systemics were 7.2 times more likely (95% CI: 1.6-31.6). (4) Conclusions: Country of residence and treatment regimen are associated with different COVID-19 vaccination rates in psoriasis patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Korouri</LastName><ForeName>Edwin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valenzuela</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1032-9347</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, University of Chile, Santiago 8330111, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Internacional de Estudios Clínicos, Probity Medical Research, Santiago 8420383, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romiti</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Dermatology, School of Medicine, University of São Paulo, São Paulo 05508-220, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didaskalu</LastName><ForeName>Johannes A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egeberg</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Bispebjerg Hospital, 2400 Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, 1172 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oon</LastName><ForeName>Hazel H</ForeName><Initials>HH</Initials><Identifier Source="ORCID">0000-0001-7607-3124</Identifier><AffiliationInfo><Affiliation>National Skin Centre, Singapore 308205, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Skin Research Institute of Singapore (SRIS), Singapore 308232, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maul</LastName><ForeName>Lara Valeska</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kingston</LastName><ForeName>Paige</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Margaret Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artiga</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0002-0089-959X</Identifier><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguero</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA 90007, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maul</LastName><ForeName>Julia-Tatjana</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0002-9914-1545</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>April W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Life (Basel)</MedlineTA><NlmUniqueID>101580444</NlmUniqueID><ISSNLinking>2075-1729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">biologics</Keyword><Keyword MajorTopicYN="N">global</Keyword><Keyword MajorTopicYN="N">psoriasis</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>F.V. has been a speaker for AbbVie, Jannsen, Novartis, Pfizer, and Leo, participated in advisory boards for AbbVie, Boehringer, Jannsen, Novartis, Pfizer, and Leo, and participated in clinical trials with AbbVie, Jannsen, Novartis, and Pfizer. R.R. is/has served as a scientific consultant, speaker, or clinical study investigator for AbbVie, Boehringer Ingelheim, Galderma, Janssen-Cilag, Eli-Lilly, Leo-Pharma, Novartis, Pfizer, Sanofi, TEVA, and UCB. Compensation (honoraria). A.E. received research funding (paid to institution) from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, and Boehringer Ingelheim, as well as honoraria as consultant and/or speaker (personal fees) from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim, and Janssen Pharmaceuticals. H.H.O. is a speaker, advisory board member, and researcher for Galderma, Janssen, and Novartis. She has also been a speaker and advisory board member for AbbVie, Boehringer Ingelheim, and Eli Lilly. L.V.M. has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by Almirall, Amgen, Eli Lilly, Incyte, MSD, Novartis, Pierre Fabre, Roche, and Sanofi outside of the current work. J.T.M. has served as a research investigator and/or scientific advisor to AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, and UCB. A.W.A. has served as a research investigator, scientific advisor, or speaker to AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer. The remaining authors have no relationships to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459597</ArticleId><ArticleId IdType="pmc">PMC11509075</ArticleId><ArticleId IdType="doi">10.3390/life14101297</ArticleId><ArticleId IdType="pii">life14101297</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gudjonsson J.E., Elder J.T. Psoriasis: Epidemiology. Clin. Dermatol. 2007;25:535–546. doi: 10.1016/j.clindermatol.2007.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clindermatol.2007.08.007</ArticleId><ArticleId IdType="pubmed">18021890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfand J.M., Armstrong A.W., Bell S., Anesi G.L., Blauvelt A., Calabrese C., Dommasch E.D., Feldman S.R., Gladman D., Kircik L., et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J. Am. Acad. Dermatol. 2021;84:1254–1268. doi: 10.1016/j.jaad.2020.12.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.12.058</ArticleId><ArticleId IdType="pmc">PMC7788316</ArticleId><ArticleId IdType="pubmed">33422626</ArticleId></ArticleIdList></Reference><Reference><Citation>Menter A., Strober B.E., Kaplan D.H., Kivelevitch D., Prater E.F., Stoff B., Armstrong A.W., Connor C., Cordoro K.M., Davis D.M., et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 2019;80:1029–1072. doi: 10.1016/j.jaad.2018.11.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2018.11.057</ArticleId><ArticleId IdType="pubmed">30772098</ArticleId></ArticleIdList></Reference><Reference><Citation>Nast A., Smith C., Spuls P.I., Avila Valle G., Bata-Csörgö Z., Boonen H., De Jong E.M.G.J., Garcia-Doval I., Gisondi P., Kaur-Knudsen D., et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris—Part 1: Treatment and monitoring recommendations. J. Eur. Acad. Dermatol. Venereol. 2020;34:2461–2498. doi: 10.1111/jdv.16915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.16915</ArticleId><ArticleId IdType="pubmed">33349983</ArticleId></ArticleIdList></Reference><Reference><Citation>Nast A., Smith C., Spuls P.I., Avila Valle G., Bata-Csörgö Z., Boonen H., De Jong E., Garcia-Doval I., Gisondi P., Kaur-Knudsen D., et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris—Part 2: Specific clinical and comorbid situations. J. Eur. Acad. Dermatol. Venereol. 2021;35:281–317. doi: 10.1111/jdv.16926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.16926</ArticleId><ArticleId IdType="pubmed">33547728</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccinations: How Should Vaccinations in People with Psoriasis Who Are Planning or Receiving Systemic Immune-Modifying Treatment Be Managed? European Dermatology Forum.  [(accessed on 11 September 2023)].  Available online:  https://www.guidelines.edf.one//uploads/attachments/clhro09jz0tleyxjrn1a0vayt-35-vaccinations-mar-2023.pdf.</Citation></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Self W.H., Adams K., Gaglani M., Ginde A.A., McNeal T., Ghamande S., Douin D.J., Talbot H.K., Casey J.D., et al. Association between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021;326:2043–2054. doi: 10.1001/jama.2021.19499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.19499</ArticleId><ArticleId IdType="pmc">PMC8569602</ArticleId><ArticleId IdType="pubmed">34734975</ArticleId></ArticleIdList></Reference><Reference><Citation>Maul J.T., Fröhlich F., Maul L.V., Stunnenberg R., Valenzuela F., De La Cruz C., Vera-Kellet C., Armijo D., Cesar W.G., Carvalho A., et al. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis. Br. J. Dermatol. 2023;188:533–541. doi: 10.1093/bjd/ljac128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bjd/ljac128</ArticleId><ArticleId IdType="pubmed">36653920</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela F., De La Cruz C., Lecaros C., Fernández J., Hevia G., Maul L.V., Vera-Kellet C., Egeberg A., Armijo D., Pizarro C., et al. Comorbidities in Chilean patients with psoriasis: A Global Healthcare Study on Psoriasis. Clin. Exp. Dermatol. 2022;47:2234–2241. doi: 10.1111/ced.15384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ced.15384</ArticleId><ArticleId IdType="pmc">PMC10092698</ArticleId><ArticleId IdType="pubmed">35988043</ArticleId></ArticleIdList></Reference><Reference><Citation>Maul J.T., Maul L.V., Didaskalu J.A., Valenzuela F., Romiti R., Peterson H., Korouri E., Novoa F., Oon H.H., Zheng M., et al. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis. Acta Derm. Venereol. 2024;104:adv20329. doi: 10.2340/actadv.v104.20329.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/actadv.v104.20329</ArticleId><ArticleId IdType="pmc">PMC10949083</ArticleId><ArticleId IdType="pubmed">38470165</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu E., Ritchie H., Ortiz-Ospina E., Roser M., Hasell J., Appel C., Giattino C., Rodés-Guirao L. A global database of COVID-19 vaccinations. Nat. Hum. Behav. 2021;5:947–953. doi: 10.1038/s41562-021-01122-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41562-021-01122-8</ArticleId><ArticleId IdType="pubmed">33972767</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo C., Villalobos Dintrans P., Maddaleno M. The successful COVID-19 vaccine rollout in Chile: Factors and challenges. Vaccine X. 2021;9:100114. doi: 10.1016/j.jvacx.2021.100114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2021.100114</ArticleId><ArticleId IdType="pmc">PMC8425670</ArticleId><ArticleId IdType="pubmed">34518818</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Yang H., Yang M., Tan H. The Role of Vaccines in COVID-19 Control Strategies in Singapore and China. Health Policy Technol. 2022;11:100620. doi: 10.1016/j.hlpt.2022.100620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlpt.2022.100620</ArticleId><ArticleId IdType="pmc">PMC8957379</ArticleId><ArticleId IdType="pubmed">35369127</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera X., Mundt A.P., Araos R., Weitzel T. The Story behind Chile’s Rapid Rollout of COVID-19 Vaccination. Travel Med. Infect. Dis. 2021;42:102092. doi: 10.1016/j.tmaid.2021.102092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2021.102092</ArticleId><ArticleId IdType="pmc">PMC8154192</ArticleId><ArticleId IdType="pubmed">34051353</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng W., Yan X., Zhao Z., Yang J., Yu H. COVID-19 vaccination program in the mainland of China: A subnational descriptive analysis on target population size and current progress. Infect. Dis. Poverty. 2021;10:124. doi: 10.1186/s40249-021-00909-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-021-00909-1</ArticleId><ArticleId IdType="pmc">PMC8517558</ArticleId><ArticleId IdType="pubmed">34654478</ArticleId></ArticleIdList></Reference><Reference><Citation>Desson Z., Kauer L., Otten T., Peters J.W., Paolucci F. Finding the way forward: COVID-19 vaccination progress in Germany, Austria and Switzerland. Health Policy Technol. 2022;11:100584. doi: 10.1016/j.hlpt.2021.100584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlpt.2021.100584</ArticleId><ArticleId IdType="pmc">PMC8627596</ArticleId><ArticleId IdType="pubmed">34868834</ArticleId></ArticleIdList></Reference><Reference><Citation>Federal Office of Public Health.  [(accessed on 26 September 2024)].  Available online:  https://www.bag.admin.ch/bag/en/home/krankheiten/krankheiten-im-ueberblick/coronavirus/covid-19/impfen.html#:~:text=Costs,pay%20for%20such%20vaccination%20themselves.</Citation></Reference><Reference><Citation>ECNS.  [(accessed on 26 September 2024)].  Available online:  https://www.ecns.cn/news/2021-01-09/detail-ihafqmaz1834647.shtml.</Citation></Reference><Reference><Citation>Singapore Ministry of Health.  [(accessed on 26 September 2024)]; Available online:  https://www.moh.gov.sg/covid-19/vaccination.</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services.  [(accessed on 26 September 2024)]; Available online:  https://www.hhs.gov/coronavirus/covid-19-care-uninsured-individuals/index.html.</Citation></Reference><Reference><Citation>U.S. Centers for Disease Control and Prevention.  [(accessed on 26 September 2024)]; Available online:  https://www.cdc.gov/vaccines-adults/recommended-vaccines/how-to-pay-adult-vaccines.html.</Citation></Reference><Reference><Citation>Rezende R.P.V., Braz A.S., Guimarães M.F.B., Ribeiro S.L.E., Vieira R.M.R.A., Bica B.E., Cruz V.A., Machado K.L.L.L., Carvalho J.S., Monticielo O.A., et al. Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases. Vaccine. 2021;39:6454–6459. doi: 10.1016/j.vaccine.2021.09.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.09.057</ArticleId><ArticleId IdType="pmc">PMC8463330</ArticleId><ArticleId IdType="pubmed">34600751</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahier J.F., Moutschen M., Van Gompel A., Van Ranst M., Louis E., Segaert S., Masson P., De Keyser F. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology. 2010;49:1815–1827. doi: 10.1093/rheumatology/keq183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keq183</ArticleId><ArticleId IdType="pmc">PMC2936949</ArticleId><ArticleId IdType="pubmed">20591834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wack S., Patton T., Ferris L.K. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. J. Am. Acad. Dermatol. 2021;85:1274–1284. doi: 10.1016/j.jaad.2021.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2021.07.054</ArticleId><ArticleId IdType="pmc">PMC8336973</ArticleId><ArticleId IdType="pubmed">34363909</ArticleId></ArticleIdList></Reference><Reference><Citation>Croce E., Hatz C., Jonker E.F., Visser L.G., Jaeger V.K., Bühler S. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation—A systematic review of randomized trials, observational studies and case reports. Vaccine. 2017;35:1216–1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">28162821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Xie F., Delzell E., Chen L., Winthrop K.L., Lewis J.D., Saag K.G., Baddley J.W., Curtis J.R. Association between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection among Older Patients with Selected Immune-Mediated Diseases. JAMA. 2012;308:43–49. doi: 10.1001/jama.2012.7304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.7304</ArticleId><ArticleId IdType="pmc">PMC3683869</ArticleId><ArticleId IdType="pubmed">22760290</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahil S.K., Dand N., Mason K.J., Yiu Z.Z., Tsakok T., Meynell F., Coker B., McAteer H., Moorhead L., Mackenzie T., et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—Insights from a global registry–based study. J. Allergy Clin. Immunol. 2020;147:60–71. doi: 10.1016/j.jaci.2020.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.10.007</ArticleId><ArticleId IdType="pmc">PMC7566694</ArticleId><ArticleId IdType="pubmed">33075408</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousaf A., Gayam S., Feldman S., Zinn Z., Kolodney M. Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study. J. Am. Acad. Dermatol. 2021;84:70–75. doi: 10.1016/j.jaad.2020.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.09.009</ArticleId><ArticleId IdType="pmc">PMC7484805</ArticleId><ArticleId IdType="pubmed">32926977</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri S.R., Pacifico A., Malagoli P., Bianchi V.G., Pregliasco F.E., Del Fabbro M., Damiani G. Heterologous versus homologous primary and booster COVID-19 vaccination do not increase flare rate in patients with psoriasis and/or psoriatic arthritis: Insights from a real-life, multicenter, case–control study. J. Eur. Acad. Dermatol. Venereol. 2023;37:6. doi: 10.1111/jdv.18943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.18943</ArticleId><ArticleId IdType="pubmed">36734591</ArticleId></ArticleIdList></Reference><Reference><Citation>Gisondi P., Geat D., Bellinato F., Girolomoni G. Use of biologics during the COVID-19 pandemic: Lessons learned from psoriasis. Expert Opin. Biol. Ther. 2022;22:1521–1529. doi: 10.1080/14712598.2022.2110467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2022.2110467</ArticleId><ArticleId IdType="pubmed">35930356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>